Entrada Therapeutics (TRDA) vs Yarrow Bioscience (YARW)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Yarrow Bioscience (YARW) has outperformed Entrada Therapeutics (TRDA) over the past year, losing 3.1% versus a loss of 25.6%. Yarrow Bioscience is the larger company by market cap ($170.4 million vs $170.2 million), about 1.0 times the size. Entrada Therapeutics converts more of its revenue into profit, with a net margin of -565.5% versus -4646.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | TRDA | YARW |
|---|---|---|
| Share price | $4.37 | $18.31 |
| Market cap | $170.15M | $170.36M |
| 1-day change | -8.58% | -8.45% |
| YTD return | -57.49% | -36.86% |
| 1-year return | -25.55% | -3.12% |
| 5-year return | — | -98.22% |
| EPS (TTM) | $-3.96 | — |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $25.42M | $570.00K |
| Revenue growth (YoY) | -87.94% | +13.77% |
| Net income (latest FY) | $-143.75M | $-26.48M |
| Operating margin | -621.13% | -5219.12% |
| Net margin | -565.48% | -4646.14% |
| 52-week high | $16.45 | $46.95 |
| 52-week low | $4.11 | $16.05 |
| Distance from 52-week high | -73.43% | -61.00% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +334.78% | +211.31% |
| Average volume | 355.10K | 92.05K |
| Shares outstanding | 38.94M | 9.30M |
| Employees | 152 | 7 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- YARW has outperformed TRDA by 22.4 percentage points over the past year.
- Entrada Therapeutics is more profitable, keeping -565.5 cents of every revenue dollar as net income versus -4646.1 cents for Yarrow Bioscience.
- Yarrow Bioscience grew revenue faster in its latest fiscal year (+13.77% vs -87.94%).
About Entrada Therapeutics
TRDA stock →Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 152 employees
About Yarrow Bioscience
YARW stock →Yarrow Bioscience, Inc. operates as a clinical-stage biotechnology company that engages in developing transformative therapies for autoimmune thyroid diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
TRDA vs YARW FAQ
Which is bigger, Entrada Therapeutics or Yarrow Bioscience?
Yarrow Bioscience (YARW) is larger, with a market capitalization of $170.36M compared with $170.15M for Entrada Therapeutics (TRDA).
Which stock has performed better over the past year, TRDA or YARW?
YARW returned -3.12% over the past 12 months, compared with -25.55% for TRDA (price return, excluding dividends). Past performance does not predict future results.
Are Entrada Therapeutics and Yarrow Bioscience in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.